Immune cells were significantly reduced as a percentage of total live cells by treatment with MEK inhibitor or SHP2 inhibitor, from 41% of total tumor cells in vehicle-treated tumors to 6.3% in MEKi-treated and 5.3% in SHP2i-treated tumors (Fig 2B). Here, PTPN11 is linked to neoplasm.